Last updated on February 2018

A Study of IMRT in Primary Bone and Soft Tissue Sarcoma

Brief description of study

IMRiS is a phase II trial which aims to assess the feasibility, efficacy and toxicity of Intensity Modulated Radiotherapy (IMRT) in three different cohorts of patients with primary bone and soft tissue sarcoma and to demonstrate whether IMRT can improve on current clinical outcomes.

Cohort 1 of the trial is now closed to recruitment.

Detailed Study Description

IMRiS is a prospective multicentre phase II trial of Intensity Modulated Radiotherapy (IMRT). The trial is aiming to evaluate the role of intensity modulated radiotherapy (IMRT) in soft tissue and bone sarcomas. Three separate sarcoma cohorts will be studied and will be analysed separately. Patients will be enrolled in one of three cohorts depending on the type of sarcoma they have:

Cohort 1- Patients with Limb/limb girdle soft tissue sarcoma receiving (neo)-adjuvant radiotherapy. (closed to recruitment)

Cohort 2- Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy.

Cohort 3- Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant radiotherapy.

Dose schedules for each Cohort have been indicated in the Trial Arm description.

Radiotherapy will be delivered with fixed beam IMRT, arc IMRT techniques, or tomotherapy. All trial patients will be followed up until death or a maximum of three years from the date of registration in the trial.

The theoretical advantage to IMRT is the potential reduction in late toxicity and subsequent potential for functional improvement. There have been no prospective studies to date powered to address this, particularly where IMRT is used post-operatively. IMRiS cohort 1 will address this question and establish if the use of IMRT will reduce late normal tissue toxicity.

In cohorts 2 & 3, the aim is to establish if the use of IMRT will enable the achievement of a radiotherapy treatment plan that delivers the optimal dose while keeping within normal tissue tolerances. There have been no clinical trials of IMRT in Ewing sarcoma and there is very little published on the use of IMRT in high grade bone sarcomas and chordomas. It is important to establish the feasibility of IMRT to achieve the required radiation doses to the tumour, and to prospectively document the side effects of treatment in this setting. IMRiS will address this in cohort 2 and cohort 3.

Clinical Study Identifier: NCT02520128

Find a site near you

Start Over

Northampton General Hospital

Northampton, United Kingdom
  Connect »

Velindre Hospital

Cardiff, United Kingdom
  Connect »

Belfast City Hospital

Belfast, United Kingdom
  Connect »

Adenbrookes' Hospital

Cambridge, United Kingdom
  Connect »

Royal Derby Hospital

Derby, United Kingdom
  Connect »

Clatterbridge Cancer Centre

Merseyside, United Kingdom
  Connect »

Singleton Hospital

Swansea, United Kingdom
  Connect »

Western General Hospital

Edinburgh, United Kingdom
  Connect »

Churchill Hospital

Oxford, United Kingdom
  Connect »

Queen Elizabeth Hospital

Birmingham, United Kingdom
  Connect »

Cheltenham Hospital

Cheltenham, United Kingdom
  Connect »

Royal Preston Hospital

Lancashire, United Kingdom
  Connect »

Leicester Royal Infirmary

Leicester, United Kingdom
  Connect »

The Christie Hospital

Manchester, United Kingdom
  Connect »

Nottingham City Hospital

Nottingham, United Kingdom
  Connect »

Derriford Hospital

Plymouth, United Kingdom
  Connect »

Weston Park Hospital

Sheffield, United Kingdom
  Connect »

Southampton General Hospital

Southampton, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.